Biotech challenger wants a bite of a huge market - starts trialling new eczema treatments

Biotech company Union Therapeutics has treated the first patient in its phase II trial of the company's drug candidate, which is a potential new treatment for atopic dermatitis.

Morten Boesen, financical director at Union Therapeutics, is seeing dollar signs with the development of the company's new potential eczema treatment. Photo: Photo: Union Therapeutics

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles